(NASDAQ: OCS) Oculis Holding Ag's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.2%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.65%.
Oculis Holding Ag's earnings in 2026 is -$121,276,923.On average, 12 Wall Street analysts forecast OCS's earnings for 2026 to be -$112,177,735, with the lowest OCS earnings forecast at -$121,601,881, and the highest OCS earnings forecast at -$99,018,674. On average, 11 Wall Street analysts forecast OCS's earnings for 2027 to be -$112,841,582, with the lowest OCS earnings forecast at -$152,610,361, and the highest OCS earnings forecast at -$78,824,076.
In 2028, OCS is forecast to generate -$93,838,186 in earnings, with the lowest earnings forecast at -$148,534,216 and the highest earnings forecast at -$2,605,755.